Loading, Please Wait...
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that updated data from its ongoing Phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), will be presented in an oral presentation at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, Netherlands, June 13-16, 2019.
In an additional oral presentation, Forty Seven will present initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These data in AML and MDS will have been previously presented in a poster session on Monday, June 3, 2019 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
Details on the presentations are as follows:
Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 with rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1b/2 results
Oral Session Title: Aggressive Lymphomas – New Agents
Presentation Date & Time: Saturday, June 15, 2019 from 16:15-16:30 CEST (10:15 a.m. – 10:30 a.m. ET)
Abstract Code: S867
Location: Hall 5
Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 is active and well tolerated alone or in combination with azacitidine in AML and MDS patients: initial phase 1b results
Oral Session Title: New Therapies in AML
Presentation Date & Time: Saturday, June 15, 2019 from 16:30-16:45 CEST (10:30 a.m. – 10:45 a.m. ET)
Abstract Code: S878
Location: Elicium 2
The accepted abstracts are now available online on the EHA website: https://ehaweb.org/congress/eha24/key-information/.
About Forty Seven Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven’s lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with solid tumors, acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin’s lymphoma, ovarian cancer and colorectal carcinoma.
For more information please visit www.fortyseveninc.com or contact firstname.lastname@example.org.
For journalist enquiries please contact Sarah Plumridge at email@example.com or phone (312) 506-5219.
For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at firstname.lastname@example.org or phone (212) 362-1200.